CVS HEALTH 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- CVS Health reported 3rd quarter 2026 revenue of over $108 billion, adjusted operating income of nearly $4.2 billion, adjusted EPS of $2.09, and cash flow from operations of approximately $4.7 billion.
- Adjusted EPS increased over 30% from the prior year quarter, with earnings growth across all operating segments.
- Healthcare Benefits adjusted operating income was approximately $900 million, an increase of nearly $600 million from the prior year quarter; the medical benefit ratio was 91.3%, an improvement of approximately 150 basis points.
- Health Services adjusted operating income was $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements.
- Pharmacy and Consumer Wellness adjusted operating income was over $1.6 billion, an increase of over 10% from the prior year, with same-store prescription volumes increasing nearly 4%.
- Year-to-date cash flow from operations was $15.3 billion, and CVS Health had returned nearly $2.6 billion to shareholders through its dividend so far in 2026.
- CVS Health announced its intention to separate into two independent publicly traded companies: a healthcare solutions company retaining Aetna, Caremark, Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health, and CVS Pharmacy, comprising retail pharmacy stores, mail order, MinuteClinic, and Health100.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to CVS Health's third quarter 2026 earnings call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the question-and-answer session. As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call to Larry McGrath.
Larry, please proceed. Good morning, and welcome to the CVS Health third quarter 2026 earnings and business update call and webcast.
I'm Larry McGrath, Executive Vice President of Capital Markets at CVS Health. I'm joined this morning by David Joyner, Chairman and Chief Executive Officer, and Brian Newman, Chief Financial Officer. Following our prepared remarks, we'll host a question-and-answer session that will include additional members of the leadership team. Our press releases and slide presentations have been posted to our website, along with our Form 10-Q filed this morning with the SEC. Today's call is also being broadcast on our website. During this call, we'll make certain forward-looking statements. Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results.
We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties, in particular those that are described in the cautionary statement concerning forward-looking statements and risk factors in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q filed this morning, and our recent filings on Form 8-K, including this morning's earnings press release. During this call, we'll use certain non-GAAP measures when talking about the company's financial performance and financial condition, and you can find a reconciliation of these non-GAAP measures in this morning's press release and in the reconciliation document posted to the investor relations portion of our website. With that, I'd like to turn the call over to David.
David? Thank you, Larry, and good morning, everyone.
Our organization has a long and distinguished history, and in my 40 years at this company, there has been one constant: we act, we evolve, and we proactively shape the future of healthcare. Today, we announced our intention to separate into two independent publicly traded companies. This decision marks the next important chapter in the evolution of CVS Health. We are creating two distinct leaders in healthcare. The first will be a healthcare solutions company that brings together medical, pharmacy, specialty, and care delivery capabilities integrated where it matters. In the interim period, we are referring to this business as CVS Health. The second company will be a leading national retail pharmacy and community healthcare company. This business will be named CVS Pharmacy.
Both companies will be led by experienced leadership teams, have a clear right to win in their respective markets, and we expect will be supported by solid investment-grade balance sheets, enabling each company to pursue disciplined and tailored capital allocation. We take this action from a position of strength, which you can see in the consistent progress we've made since 2024, as well as in the third quarter results and the updated guidance we announced this morning. This quarter, we generated adjusted operating income of $4.2 billion and adjusted EPS of $2.09. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted EPS guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10.
We are also updating our full year expectation for cash flow from operations to at least $15.5 billion. With this latest update, our 2026 adjusted EPS guidance is now more than $1 above our initial expectations for 2026, and our cash flow from operations outlook has increased by more than $5.5 billion for the year. This progress clearly reflects our growing momentum. I'll now ask Brian to provide more details on the results this quarter, our updated full year 2026 guidance, and perspective on the factors shaping our 2027 expectations. I will then come back to provide more details on our announcement.
Brian? Thank you, David, and good morning.
I will cover four key topics in my remarks this morning. First, an update on our third quarter results. Second, I'll discuss cash flow, the balance sheet, and capital deployment. After that, I will provide an updated financial outlook for 2026. Finally, I will share some headwinds and tailwinds as we look ahead to 2027. Our third quarter results demonstrate the discipline with which we continue to manage the enterprise. We once again delivered on our commitments and raised our full year outlook for revenue, adjusted EPS, and cash flow from operations. Our execution has significantly strengthened our balance sheet, allowing us to achieve target leverage ahead of schedule, and will enable us to resume our share repurchase program in the fourth quarter. Let me start by highlighting some of our enterprise results in the quarter.
We generated over $108 billion of revenue and delivered nearly $4.2 billion of adjusted operating income, once again reflecting earnings growth across all of our operating segments. We delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. Finally, in the quarter, we generated cash flow from operations of approximately $4.7 billion, bringing our year-to-date cash flow from operations to $15.3 billion. Turning now to each of our segments. In healthcare benefits, we continue to make strong progress in our return to target margins. In the quarter, we delivered adjusted operating income of approximately $900 million, an increase of nearly $600 million from the prior year quarter. Our medical benefit ratio was 91.3%, an improvement of approximately 150 basis points from the prior year.
These results were primarily driven by improved underlying performance in our Medicare business. Across our businesses, we continue to successfully navigate elevated trends that remain above historical levels throughout the industry, but were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations, driven by pockets of favorability as a result of strong medical cost management and disciplined pricing. We remain confident in the adequacy of our reserves. In our Health Services segment, we continue to execute against our objectives. During the quarter, we delivered adjusted operating income of $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements. Results in our pharmacy services business were in line with our expectations during the quarter, including performance in both our 340B business and rebate guarantees.
Healthcare delivery also performed as expected as we continue to drive improvement in the business. Our Pharmacy and Consumer Wellness segment delivered another strong quarter. We generated adjusted operating income of over $1.6 billion, an increase of over 10% from the prior year, primarily driven by core pharmacy strength, including a nearly 4% increase in same-store prescription volumes, partially offset by continued business investments and the impact of consumer dynamics. Turning now to cash flow and the balance sheet. Year to date, we have generated cash flow from operations of $15.3 billion, reflecting strong earnings as well as the impact of improvements in working capital. So far in 2026, we have returned nearly $2.6 billion to our shareholders through our shareholder dividend. We ended the quarter with nearly $6 billion of cash at the parent and unrestricted subsidiaries.
As I mentioned earlier, we have made significant progress strengthening our balance sheet and have achieved our leverage goal ahead of schedule. This improved position, combined with our strong cash flow, will enable us to resume our share repurchase program in the fourth quarter. Shifting now to our guidance for 2026. We are increasing our full-year 2026 guidance for adjusted EPS to at least $8.20, an increase of $0.20 from the midpoint of our previous outlook. We now also expect our full-year total revenues to be at least $420 billion. In our Health Care Benefits segment, we now expect full-year adjusted operating income to be at least $5.4 billion, an increase of $200 million relative to the midpoint of our prior outlook.
We now expect our full-year MBR to be in the lower half of our previously discussed range of 89.75%, plus or minus 25 basis points. This outlook continues to maintain a respectful and prudent view of medical cost trends. In our Pharmacy and Consumer Wellness segment, we now expect full-year adjusted operating income of at least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% growth from the prior year. This reflects our strong performance in the quarter and our updated expectations for the remainder of the year. We are also reiterating our full-year adjusted operating income outlook for our Health Services segment. In aggregate, we now expect full-year enterprise adjusted operating income to be at least $17.05 billion.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
